Swooning markets a concern for stem cell companies

Recent setbacks in the stock market are particularly troubling for public stem cell companies, say analysts. With government funding to the field tightly restricted, the public markets have been a key source of funds for these developers. But investors tend to take a particularly skeptical view of early-stage development programs that are hard to understand. Merchant banker Steve Burrill told MarketWatch, though, that there are a number of potential sources of cash for stem cell companies around the world.

- read the report from MarketWatch

Suggested Articles

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.